title: Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe--a Hungarian nationwide observational study.
abstract: BACKGROUND
  Infliximab (IFX) has proven to be an effective addition to the therapeutic arsenal for refractory, fistulizing, and steroid dependent Crohn's disease (CD), with efficacy in the induction and maintenance of clinical remission of CD. Our objective in this study is to report the nationwide, multicenter experience with IFX induction therapy for CD in Hungary.
  
  
  METHODS
  During a 6-year-period, beginning in 2000, a total of 363 CD patients were treated with IFX as induction therapy (5 mg/kg IFX infusions given at week 0, 2 and 6) at eleven centers in Hungary in this observational study. Data analysis included patient demographics, important disease parameters and the outcome of IFX induction therapy.
  
  
  RESULTS
  Three hundred and sixty three patients (183 women and 180 men) were treated with IFX since 2000. Mean age was 33.5 +/- 11.2 years and the mean duration of disease was 6.7 +/- 6.1 years. The population included 114 patients (31.4%) with therapy-refractory CD, 195 patients (53.7%) with fistulas, 16 patients (4.4%) with both therapy-refractory CD and fistulas, and 26 patients (7.2%) with steroid dependent CD. Overall response rate was 86.2% (313/363). A higher response rate was observed in patients with shorter disease duration (p = 0.05, OR:0.54, 95%CI:0.29-0.99) and concomitant immunosuppressant therapy (p = 0.05, OR: 2.03, 95%CI:0.165-0.596). Concomitant steroid treatment did not enhance the efficacy of IFX induction therapy. Adverse events included 34 allergic reactions (9.4%), 17 delayed type hypersensitivity (4.7%), 16 infections (4.4%), and 3 malignancies (0.8%).
  
  
  CONCLUSIONS
  IFX was safe and effective treatment in this cohort of Hungarian CD patients. Based on our experience co-administration of immunosuppressant therapy is suggested in patients receiving IFX induction therapy. However, concomitant steroid treatment did not enhanced the efficacy of IFX induction therapy.
authors.affiliation: 2nd Department of Medicine, Semmelweis University, Budapest, Hungary. mihpal@yahoo.co.uk
authors.forename: Pál
authors.initials: P
authors.lastname: Miheller
authors.forename: Péter L
authors.initials: PL
authors.lastname: Lakatos
authors.forename: Gábor
authors.initials: G
authors.lastname: Horváth
authors.forename: Tamás
authors.initials: T
authors.lastname: Molnár
authors.forename: Tamás
authors.initials: T
authors.lastname: Szamosi
authors.forename: Zsófia
authors.initials: Z
authors.lastname: Czeglédi
authors.forename: Agnes
authors.initials: A
authors.lastname: Salamon
authors.forename: József
authors.initials: J
authors.lastname: Czimmer
authors.forename: György
authors.initials: G
authors.lastname: Rumi
authors.forename: Károly
authors.initials: K
authors.lastname: Palatka
authors.forename: Mária
authors.initials: M
authors.lastname: Papp
authors.forename: Zsolt
authors.initials: Z
authors.lastname: Jakab
authors.forename: Andrea
authors.initials: A
authors.lastname: Szabó
authors.forename: András
authors.initials: A
authors.lastname: Gelley
authors.forename: László
authors.initials: L
authors.lastname: Lakatos
authors.forename: Zsolt
authors.initials: Z
authors.lastname: Barta
authors.forename: Csaba
authors.initials: C
authors.lastname: Balázs
authors.forename: István
authors.initials: I
authors.lastname: Rácz
authors.forename: Margit
authors.initials: M
authors.lastname: Zeher
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Döbrönte
authors.forename: István
authors.initials: I
authors.lastname: Altorjay
authors.forename: Béla
authors.initials: B
authors.lastname: Hunyady
authors.forename: László
authors.initials: L
authors.lastname: Simon
authors.forename: János
authors.initials: J
authors.lastname: Papp
authors.forename: János
authors.initials: J
authors.lastname: Banai
authors.forename: Ferenc
authors.initials: F
authors.lastname: Nagy
authors.forename: János
authors.initials: J
authors.lastname: Lonovics
authors.forename: László
authors.initials: L
authors.lastname: Ujszászy
authors.forename: Györgyi
authors.initials: G
authors.lastname: Muzes
authors.forename: László
authors.initials: L
authors.lastname: Herszényi
authors.forename: Zsolt
authors.initials: Z
authors.lastname: Tulassay
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use*; D003424:Crohn Disease / Q000188:drug therapy*; D005260:Female; D006801:Humans; D006814:Hungary; D006967:Hypersensitivity / Q000209:etiology; D000069285:Infliximab; D016015:Logistic Models; D008137:Longitudinal Studies; D008297:Male; D012074:Remission Induction; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000069285:Infliximab